A single-arm, open-label, multi-centre pilot study evaluating the efficacy and safety of Ro 25-8310 combination therapy with Ro 20-9963 in pateints with chronic hepatitis C attending a methdone clinic

This study is testing a combination of hepatitis C treatments for people who are currently on a methadone program (or similar) for opioid dependence. Hepatitis C is a liver infection spread through blood contact, and it is common among people who have injected drugs. The study aims to see whether people receiving medication-assisted treatment for drug dependence can successfully complete and benefit from hepatitis C treatment. You may be eligible if: - You have had hepatitis C infection confirmed by blood tests for more than 6 months - Your blood tests show the hepatitis C virus is still active in your body - You have had elevated liver enzymes on at least two occasions in the past 6 months - A liver biopsy has confirmed chronic hepatitis C - You have injected drugs within the last 6 months before the screening visit - You are currently on a pharmacotherapy programme such as Methadone, Buprenorphine, or Naltrexone You may NOT be eligible if: - You have tested positive for hepatitis A IgM, hepatitis B surface antigen, hepatitis B IgM, or HIV - You have another medical condition causing chronic liver disease besides hepatitis C Talk to your doctor about whether this trial might be right for you.